Cutler Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,106
| Closed | -$315K | – | 3787 |
|
|
2023
Q2 | $315K | Sell |
1,106
-1,763
| -61% | -$525K | 0.04% | 462 |
|
|
2023
Q1 | $797K | Sell |
2,869
-21,709
| -88% | -$6.01M | 0.08% | 247 |
|
|
2022
Q4 | $6.81M | Buy |
24,578
+8,008
| +48% | +$2.26M | 0.58% | 34 |
|
|
2022
Q3 | $4.42M | Buy |
16,570
+6,514
| +65% | +$1.38M | 0.3% | 45 |
|
|
2022
Q2 | $2.05M | Buy |
10,056
+8,191
| +439% | +$1.67M | 0.14% | 166 |
|
|
2022
Q1 | $392K | Sell |
1,865
-9,387
| -83% | -$2.04M | 0.02% | 780 |
|
|
2021
Q4 | $2.7M | Buy |
11,252
+10,599
| +1,623% | +$2.73M | 0.11% | 190 |
|
|
2021
Q3 | $184K | Buy |
653
+553
| +553% | +$181K | 0.01% | 1421 |
|
|
2021
Q2 | $34K | Sell |
100
-185
| -65% | -$56K | ﹤0.01% | 2814 |
|
|
2021
Q1 | $79K | Buy |
285
+85
| +43% | +$22.9K | ﹤0.01% | 1962 |
|
|
2020
Q4 | $48K | Hold |
200
| – | – | ﹤0.01% | 2039 |
|
|
2020
Q3 | $56K | Sell |
200
-1,284
| -87% | -$358K | ﹤0.01% | 1720 |
|
|
2020
Q2 | $397K | Sell |
1,484
-1,573
| -51% | -$473K | 0.03% | 568 |
|
|
2020
Q1 | $967K | Sell |
3,057
-3,297
| -52% | -$1M | 0.05% | 354 |
|
|
2019
Q4 | $1.89M | Buy |
6,354
+4,433
| +231% | +$1.23M | 0.12% | 158 |
|
|
2019
Q3 | $447K | Buy |
1,921
+1,621
| +540% | +$377K | 0.04% | 389 |
|
|
2019
Q2 | $70K | Buy |
+300
| New | +$69.3K | 0.01% | 1301 |
|
|
2019
Q1 | – | Sell |
-1,800
| Closed | -$567K | – | 4039 |
|
|
2018
Q4 | $541K | Buy |
1,800
+1,700
| +1,700% | +$543K | 0.05% | 316 |
|
|
2018
Q3 | $35K | Buy |
+100
| New | +$34.4K | ﹤0.01% | 1833 |
|
|
2018
Q2 | – | Sell |
-196
| Closed | -$55.1K | – | 4198 |
|
|
2018
Q1 | $53K | Sell |
196
-12,802
| -98% | -$3.97M | ﹤0.01% | 1622 |
|
|
2017
Q4 | $4.14M | Sell |
12,998
-36,897
| -74% | -$11.8M | 0.17% | 72 |
|
|
2017
Q3 | $15.6M | Sell |
49,895
-72,805
| -59% | -$21.6M | 0.59% | 19 |
|
|
2017
Q2 | $33.3M | Buy |
122,700
+89,461
| +269% | +$23.7M | 1.23% | 9 |
|
|
2017
Q1 | $9.09M | Sell |
33,239
-63,535
| -66% | -$18M | 0.38% | 46 |
|
|
2016
Q4 | $27.4M | Buy |
96,774
+2,824
| +3% | +$837K | 0.99% | 8 |
|
|
2016
Q3 | $29.4M | Buy |
93,950
+6,936
| +8% | +$2.05M | 1.32% | 7 |
|
|
2016
Q2 | $21M | Buy |
87,014
+68,143
| +361% | +$18M | 1.07% | 9 |
|
|
2016
Q1 | $4.91M | Buy |
18,871
+9,686
| +105% | +$2.56M | 0.32% | 34 |
|
|
2015
Q4 | $2.81M | Buy |
+9,185
| New | +$2.64M | 0.16% | 105 |
|
Other funds holding BIIB
Cutler Group's BIIB Position: Q3 2023 in Review
Cutler Group sold out of Biogen (BIIB) in Q3 2023, closing a stake of 1,106 shares — an estimated $315K sold.
Cutler Group first reported a position in BIIB in Q4 2015 and held it in 29 quarters. The position peaked at $33.3M in Q2 2017. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.
- Cutler Group reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
- Cutler Group sold 1,106 Biogen shares in Q3 2023, an estimated $315K.
- Cutler Group first reported a position in Biogen in Q4 2015 and held it in 29 quarters.
- Cutler Group's Biogen position peaked at $33.3M in Q2 2017.
- 965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.
Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.